World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
89
Citations
29801
World Ranking
12669
National Ranking
6479

Overview

David A. Luckenbaugh is affiliated with the National Institutes of Health in the United States. Their research spans several areas within medicine, with a focus on pharmacology, biological psychiatry, experimental and cognitive psychology, psychiatry and mental health, and pediatrics, perinatology, and child health.

The scientist has contributed to topics including:

  • Treatment of Major Depression
  • Tryptophan and brain disorders
  • Mental Health Research Topics
  • Bipolar Disorder and Treatment
  • Pharmacological Effects and Toxicity Studies
  • Adolescent and Pediatric Healthcare

David A. Luckenbaugh's recent published papers emphasize clinical and pharmacological investigations. These include:

  • The effects of ketamine on typical and atypical depressive symptoms, 2020, Acta Psychiatrica Scandinavica
  • A Double-Blind, Randomized, Placebo-Controlled 4-Week Study on the Efficacy and Safety of the Purinergic Agents Allopurinol and Dipyridamole Adjunctive to Lithium in Acute Bipolar Mania, 2020, UNC Libraries

The frequent co-authors with whom they have collaborated consist of:

  • Carlos A. Zarate
  • Lawrence T. Park
  • Steven Pennybaker
  • Matthew Hopkins
  • Ioline D. Henter

The primary venues where Luckenbaugh has published their research include:

  • Acta Psychiatrica Scandinavica
  • UNC Libraries

Best Publications

  • A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression

    Carlos A. Zarate;Jaskaran B. Singh;Paul J. Carlson;Nancy E. Brutsche

  • A Randomized Add-on Trial of an N-methyl-d-aspartate Antagonist in Treatment-Resistant Bipolar Depression

    Nancy Diazgranados;Lobna Ibrahim;Nancy E. Brutsche;Andrew Newberg

  • Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.

    Carlos A. Zarate;Nancy E. Brutsche;Lobna Ibrahim;Jose Franco-Chaves

  • A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders.

    Mark A. Frye;Terence A. Ketter;Timothy A. Kimbrell;Timothy A. Kimbrell;Robert T. Dunn

  • Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.

    Nancy DiazGranados;Lobna A. Ibrahim;Nancy E. Brutsche;Rezvan Ameli

  • Hippocampal volume, memory, and cortisol status in major depressive disorder: effects of treatment.

    Meena Vythilingam;Eric Vermetten;George M Anderson;David Luckenbaugh

  • Reward improves long-term retention of a motor memory through induction of offline memory gains

    Mitsunari Abe;Heidi Schambra;Eric M. Wassermann;Dave Luckenbaugh

  • Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH Life Chart Method

    Robert M. Post;Kirk D. Denicoff;Gabriele S. Leverich;Lori L. Altshuler

  • Reduced Serotonin Type 1A Receptor Binding in Panic Disorder

    Alexander Neumeister;Earle Bain;Allison C. Nugent;Richard E. Carson

  • Factors associated with suicide attempts in 648 patients with bipolar disorder in the Stanley Foundation Bipolar Network.

    Gabriele S. Leverich;Lori L. Altshuler;Mark A. Frye;Trisha Suppes

  • A Double-Blind, Placebo-Controlled Study of Memantine in the Treatment of Major Depression

    Carlos A. Zarate;Jaskaran B. Singh;Jorge A. Quiroz;Georgette De Jesus

  • Evidence for continuing neuropsychological impairments in depression

    Petra Weiland-Fiedler;Kristine Erickson;Tracy Waldeck;David A. Luckenbaugh

  • Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder

    Ralph W. Kupka;Lori L. Altshuler;Willem A. Nolen;Trisha Suppes

  • Early-onset bipolar disorder and treatment delay are risk factors for poor outcome in adulthood

    Robert M. Post;Gabriele S. Leverich;Ralph W. Kupka;Paul E. Keck

  • Pramipexole for bipolar II depression: a placebo-controlled proof of concept study.

    Carlos A Zarate;Jennifer L Payne;Jaskaran Singh;Jorge A Quiroz

  • An open-label trial of riluzole in patients with treatment-resistant major depression.

    Carlos A. Zarate;Jennifer L. Payne;Jorge Quiroz;Jonathan Sporn

  • Course of Improvement in Depressive Symptoms to a Single Intravenous Infusion of Ketamine vs Add-on Riluzole: Results from a 4-Week, Double-Blind, Placebo-Controlled Study

    Lobna Ibrahim;Nancy DiazGranados;Nancy DiazGranados;Jose Franco-Chaves;Nancy Brutsche

  • Reduced hippocampal volume in unmedicated, remitted patients with major depression versus control subjects.

    Alexander Neumeister;Suzanne Wood;Omer Bonne;Allison C. Nugent

  • Neural and behavioral responses to tryptophan depletion in unmedicated patients with remitted major depressive disorder and controls.

    Alexander Neumeister;Allison C. Nugent;Tracy Waldeck;Marilla Geraci

  • An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression

    Carlos A. Zarate;Jorge A. Quiroz;Jaskaran B. Singh;Kirk D. Denicoff

Frequent Co-Authors

Carlos A. Zarate
Carlos A. Zarate National Institutes of Health
Wayne C. Drevets
Wayne C. Drevets Johnson & Johnson (United States)
Dennis S. Charney
Dennis S. Charney Icahn School of Medicine at Mount Sinai
Robert M. Post
Robert M. Post George Washington University
Mark J. Niciu
Mark J. Niciu University of Iowa
Rodrigo Machado-Vieira
Rodrigo Machado-Vieira The University of Texas Health Science Center at Houston
Alexander Neumeister
Alexander Neumeister Independent Scientist / Consultant, US
Elizabeth D. Ballard
Elizabeth D. Ballard National Institutes of Health
Mark A. Frye
Mark A. Frye University of California, Los Angeles
Lori L. Altshuler
Lori L. Altshuler University of California, Los Angeles

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Aspiring medical professionals have a variety of online degree choices and career pathways in health care. Many students in the USA start with related fields before or while pursuing a medical degree. For those interested in the administrative side of healthcare, earning a him bachelor's degree online can open doors to managing patient data and health information systems.

Another popular option is pursuing the cheapest medical billing and coding online courses. This career path is vital for accurate patient records and insurance processing. For those aiming for direct patient care but seeking flexibility, there are many cheapest fnp programs that help students become Family Nurse Practitioners via online learning.

Lastly, if you want to become a registered nurse, a wide range of online nursing courses offer affordable entry points. These online degrees and certifications provide diverse opportunities to enter or advance within the healthcare field, especially for those balancing work, study, and family commitments.

Best Scientists Citing David A. Luckenbaugh

Trending Scientists